Histological scores in inflammatory bowel disease.
histology
inflammatory bowel diseases
microscopic activity
prognostic factor
therapeutic target
Journal
Journal of digestive diseases
ISSN: 1751-2980
Titre abrégé: J Dig Dis
Pays: Australia
ID NLM: 101302699
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
05
06
2020
revised:
02
09
2020
accepted:
03
09
2020
pubmed:
9
9
2020
medline:
16
9
2021
entrez:
8
9
2020
Statut:
ppublish
Résumé
The role of histology in inflammatory bowel disease (IBD) has not yet been well defined. Endoscopic mucosal healing has been proposed as a predictor of the clinical course of IBD and it is indeed considered one of the main therapeutic targets. However, it does not necessarily imply histological healing. Histological remission has been reported to be associated with a better clinical outcome than endoscopic remission only in IBD patients. These observations support the view that histology plays a role as a potential therapeutic target in Crohn's disease and ulcerative colitis. Histological scores being able to quantify the degree of microscopic activity are needed for this purpose. In the era of biologics, indication for proper treatment may benefit from the assessment of clinical and endoscopic activity, as well as histological scores. Such scores may allow us to quantify the microscopic mucosal response to treatment and to define complete healing in IBD. A validated histological score in IBD may lead to the definition of microscopic activity in clinical practice, trials and investigational settings. Several attempts to develop such scores have been reported, but few are currently used and none is applied worldwide in clinical practice. The present review summarizes the main histological scores currently used for assessing IBD activity.
Identifiants
pubmed: 32897005
doi: 10.1111/1751-2980.12937
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-22Informations de copyright
© 2020 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
Références
Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12(Suppl 1):S3-S9.
Magro F, Gionchetti P, Eliakim R, et al; European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo−anal pouch disorders. J Crohns Colitis. 2017;11(6):649-670.
Gionchetti P, Dignass A, Danese S, ECCO, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 2: surgical management and special situations. J Crohns Colitis. 2017;11(2):135-149.
Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity inulcerative colitis: what does it mean? Gut. 1991;32(2):174-178.
Rosenberg L, Nanda KS, Zenlea T, et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol. 2013;11(8):991-996.
Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65(3):408-414.
Mojtahed A, Khanna R, Sandborn WJ, et al. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2014;20(11):2092-2103.
Bryant RV, Winer S, Travis SPL, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 2014;8(12):1582-1597.
Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713-1725.
Magro F, Langner C, Driessen A, European Society of Pathology (ESP), European Crohn's and Colitis Organisation (ECCO), et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7(10):827-851.
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741-1755.
Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45(12):969-977.
Iacucci M, Ghosh S. Mucosal healing − how deep is enough? Dig Dis. 2016;34(1-2):160-164.
Gomollón F, Dignass A, Annese V, ECCO, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3-25.
US Food and Drug Administration. Ulcerative colitis: clinical trial endpoints guidance for industry. Rockville, MD: US Food and Drug Administration; 2016.
Truelove SC, Hambling MH. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. Br Med J. 1958;2(5104):1072-1077.
Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2(8044):892-895.
Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194-1201.
De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2013;19(2):429-444.
D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763-786.
Travis SPL, Higgins PDR, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;34(2):113-124.
Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013;11(12):1601-1608.e4.
Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133(4):1099-1105.
Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451-459.
Molander P, Sipponen T, Kemppainen H, et al. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. J Crohns Colitis. 2013;7(9):730-735.
Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412-422.
Baert F, Moortgat L, Van Assche G, Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138(2):463-468.
Magro F, Doherty G, Peyrin-Biroulet L, et al. ECCO position paper: harmonisation of the approach to ulcerative colitis histopathology. J Crohns Colitis. 2020;14(11):1503-1511. https://doi.org/10.1093/ecco-jcc/jjaa110.
Ward M, Webb JN. Rectal biopsy as a prognostic guide in Crohn's colitis. J Clin Pathol. 1977;30(2):126-131.
D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114(2):262-267.
Geboes K, Rutgeerts P, Opdenakker G, et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin. 2005;21(11):1741-1754.
Li K, Friedman JR, Chan D, et al. Effects of ustekinumab on histologic disease activity in patients with Crohn's disease. Gastroenterology. 2019;157(4):1019-1031.e7.
Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut. 2006;55(11):1561-1567.
Brennan GT, Melton SD, Spechler SJ, Feagins LA. Clinical implications of histologic abnormalities in ileocolonic biopsies of patients with Crohn's disease in remission. J Clin Gastroenterol. 2017;51(1):43-48.
Kruis W, Kiudelis G, Rácz I, et al; International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009;58(2):233-240.
Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med. 2005;352(24):2499-2507.
Lemmens B, Arijs I, Van Assche G, et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis. 2013;19(6):1194-1201.
Geboes K, Riddell R, Öst A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47(3):404-409.
Fernández-Blanco JI, Fernández-Díaz G, Cara C, Vera MI, Olivares D, Taxonera C. Adalimumab for induction of histological remission in moderately to severely active ulcerative colitis. Dig Dis Sci. 2018;63(3):731-737.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al; VARSITY Study Group. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215-1226.
Jauregui-Amezaga A, Geerits A, Das Y, et al. A simplified Geboes score for ulcerative colitis. J Crohns Colitis. 2017;11(3):305-313.
Gramlich T, Petras RE. Pathology of inflammatory bowel disease. Semin Pediatr Surg. 2007;16(3):154-163.
Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. Gut. 2017;66(1):43-49.
Jairath V, Peyrin-Biroulet L, Zou G, et al. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 2019;68(7):1162-1168.
Magro F, Lopes J, Borralho P, et al. Comparison of the Nancy index with continuous Geboes score: histological remission and response in ulcerative colitis. J Crohns Colitis. 2020;14(7):1021-1025.
Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut. 2017;66(1):50-58.
Magro F, Lopes J, Borralho P, et al. Comparing the continuous Geboes score with the Robarts histopathology index: definitions of histological remission and response and their relation to faecal calprotectin levels. J Crohns Colitis. 2020;14(2):169-175.
Iacucci M, Gasia MF, Hassan C, et al. Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings. Endoscopy. 2015;47(8):726-734.
Esaki M, Kubokura N, Kudo T, Matsumoto T. Endoscopic findings under narrow band imaging colonoscopy in ulcerative colitis. Dig Endosc. 2011;23(Suppl):140-142.
Hefti MM, Chessin DB, Harpaz NH, Steinhagen RM, Ullman TA. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum. 2009;52(2):193-197.
Naini BV, Cortina G. A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Hum Pathol. 2012;43(12):2187-2196.
Gong WB, Guo K, Zheng T, et al. Correlation between endoscopic and histological validated scoring indices in Crohn's disease. Dig Liver Dis. 2019;51(6):812-817.
Mosli MH, Parker CE, Nelson SA, et al. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2017;5(5):CD011256.
Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012;107(11):1684-1692.